MedWatch

Lundbeck drug shows significantly improved functioning in major depressive disorder

According to Lundbeck, new trial results demonstrate that the firm's antidepressant Brintellix significantly improves overall functioning in people suffering from severe depression.

Lundbeck EVP for R&D Johan Luthman | Photo: PR / Lundbeck

On Thursday morning, Lundbeck reported receiving positive data for the company's antidepressant Brintellix (generic name vortioxetin). In the firm's Relieve study, the drug has shown promise in improving severely depressed patients' ability to function.

A total of 994 patients took part in this study, which Lundbeck states shows significant improvements in overall functioning after three months and further improvements following a six-month period.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs